Literature DB >> 18020309

Derrubone, an inhibitor of the Hsp90 protein folding machinery.

M Kyle Hadden1, Lakshmi Galam, Jason E Gestwicki, Robert L Matts, Brian S J Blagg.   

Abstract

High-throughput screening of a library of diverse molecules has identified derrubone ( 1), an isoflavone natural product from Derris robusta, as a potent Hsp90 inhibitor. Subsequent testing in several cellular-based assays established 1 as a low micromolar inhibitor in vitro. In addition, derrubone induced the degradation of numerous Hsp90 client proteins, a hallmark effect resulting from Hsp90 inhibition. The identification of 1 as an Hsp90 inhibitor provides a new natural product scaffold upon which the development of novel Hsp90 inhibitors can be pursued.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 18020309     DOI: 10.1021/np070190s

Source DB:  PubMed          Journal:  J Nat Prod        ISSN: 0163-3864            Impact factor:   4.050


  12 in total

Review 1.  Heat shock proteins and kidney disease: perspectives of HSP therapy.

Authors:  Natalia Chebotareva; Irina Bobkova; Evgeniy Shilov
Journal:  Cell Stress Chaperones       Date:  2017-04-13       Impact factor: 3.667

Review 2.  Anticancer Inhibitors of Hsp90 Function: Beyond the Usual Suspects.

Authors:  Gaurav Garg; Anuj Khandelwal; Brian S J Blagg
Journal:  Adv Cancer Res       Date:  2016-02-10       Impact factor: 6.242

3.  A systematic protocol for the characterization of Hsp90 modulators.

Authors:  Robert L Matts; Gary E L Brandt; Yuanming Lu; Anshuman Dixit; Mehdi Mollapour; Suiquan Wang; Alison C Donnelly; Leonard Neckers; Gennady Verkhivker; Brian S J Blagg
Journal:  Bioorg Med Chem       Date:  2010-10-19       Impact factor: 3.641

Review 4.  New developments in Hsp90 inhibitors as anti-cancer therapeutics: mechanisms, clinical perspective and more potential.

Authors:  Yanyan Li; Tao Zhang; Steven J Schwartz; Duxin Sun
Journal:  Drug Resist Updat       Date:  2009 Feb-Apr       Impact factor: 18.500

5.  The synthesis and evaluation of flavone and isoflavone chimeras of novobiocin and derrubone.

Authors:  Jared R Mays; Stephanie A Hill; Justin T Moyers; Brian S J Blagg
Journal:  Bioorg Med Chem       Date:  2009-10-31       Impact factor: 3.641

6.  Synthesis and evaluation of Hsp90 inhibitors that contain the 1,4-naphthoquinone scaffold.

Authors:  M Kyle Hadden; Stephanie A Hill; Jason Davenport; Robert L Matts; Brian S J Blagg
Journal:  Bioorg Med Chem       Date:  2008-12-03       Impact factor: 3.641

Review 7.  Natural product inhibitors of Hsp90: potential leads for drug discovery.

Authors:  M W Amolins; B S J Blagg
Journal:  Mini Rev Med Chem       Date:  2009-02       Impact factor: 3.862

8.  Synthesis and Biological Evaluation of Novobiocin Core Analogues as Hsp90 Inhibitors.

Authors:  Katherine M Byrd; Chitra Subramanian; Jacqueline Sanchez; Hashim F Motiwala; Weiya Liu; Mark S Cohen; Jeffrey Holzbeierlein; Brian S J Blagg
Journal:  Chemistry       Date:  2016-04-01       Impact factor: 5.236

Review 9.  The disruption of protein-protein interactions with co-chaperones and client substrates as a strategy towards Hsp90 inhibition.

Authors:  Michael A Serwetnyk; Brian S J Blagg
Journal:  Acta Pharm Sin B       Date:  2020-11-24       Impact factor: 11.413

10.  Proteome alteration induced by hTERT transfection of human fibroblast cells.

Authors:  Gabriel D Mazzucchelli; Valérie Gabelica; Nicolas Smargiasso; Maximilien Fléron; Wilson Ashimwe; Frédéric Rosu; Marie-Claire De Pauw-Gillet; Jean-François Riou; Edwin De Pauw
Journal:  Proteome Sci       Date:  2008-04-17       Impact factor: 2.480

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.